BIOMAT Database Logo BIOMAT Database Logo

Intralipid in prophylaxis of amphotericin B nephrotoxicity. 1994

E Vita, and D J Schroeder
Drug Information Analysis Service, University of California, San Francisco 94143.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D008297 Male Males
D009181 Mycoses Diseases caused by FUNGI. Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D005217 Fat Emulsions, Intravenous Emulsions of fats or lipids used primarily in parenteral feeding. Intravenous Fat Emulsion,Intravenous Lipid Emulsion,Lipid Emulsions, Intravenous,Emulsion, Intravenous Fat,Emulsion, Intravenous Lipid,Emulsions, Intravenous Fat,Emulsions, Intravenous Lipid,Fat Emulsion, Intravenous,Intravenous Fat Emulsions,Intravenous Lipid Emulsions,Lipid Emulsion, Intravenous
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical

Related Publications

E Vita, and D J Schroeder
Reduction in the nephrotoxicity of amphotericin B when administered in 20% intralipid.
May 1997, The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses,
E Vita, and D J Schroeder
Amphotericin B nephrotoxicity.
August 1988, American family physician,
E Vita, and D J Schroeder
Amphotericin B nephrotoxicity.
January 1990, Drug safety,
E Vita, and D J Schroeder
Amphotericin B nephrotoxicity.
January 2002, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia,
E Vita, and D J Schroeder
Amphotericin B nephrotoxicity.
February 2002, The Journal of antimicrobial chemotherapy,
E Vita, and D J Schroeder
[Nephrotoxicity of amphotericin B].
January 2002, Nephrologie,
E Vita, and D J Schroeder
Nephrotoxicity of amphotericin B.
September 1994, Journal of the American College of Surgeons,
E Vita, and D J Schroeder
Amphotericin B nephrotoxicity in children.
July 2004, Journal of pediatric hematology/oncology,
E Vita, and D J Schroeder
Cytokines in mice treated with amphotericin B-intralipid.
April 2004, Medical mycology,
E Vita, and D J Schroeder
Nephrotoxicity of amphotericin B desoxycholate.
September 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Copied contents to your clipboard!